Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HBB | P68871 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252230 | 0.85 | OPRL1 (0.65) | OPRM1OPRL1DRD2POLBSIGMAR1 | |
| Hydrochloric Acid SCHEMBL6160179 | 0.84 | POLB (0.66) | OPRM1OPRL1DRD2POLBDRD3 | |
| SCHEMBL27550808 | 0.84 | OPRL1 (0.63) | OPRM1OPRL1DRD2POLBDRD3 | |
| SCHEMBL6600993 | 0.80 | OPRM1 (0.56) | OPRM1OPRL1DRD2POLBDRD3 | |
| SCHEMBL6656032 | 0.80 | OPRM1 (0.79) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6486106 | 0.80 | OPRM1 (0.79) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6602364 | 0.79 | KDM4E (0.50) | OPRM1OPRL1POLBOPRK1SIGMAR1 | |
| SCHEMBL6171176 | 0.78 | OPRD1 (0.52) | OPRD1OPRM1OPRL1DRD2POLB | |
| SCHEMBL6183759 | 0.77 | OPRD1 (0.58) | OPRD1OPRM1OPRL1DRD2POLB | |
| SCHEMBL22112062 | 0.77 | OPRM1 (0.47) | OPRD1OPRM1OPRL1DRD2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1072601-B1 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6750231-B2 | SKIN DISORDERS; GASTROINTESTINAL DISORDERS | PFIZER INC | 2004-06-15 | — | — | US | disclosed |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | GIBSON STEPHEN PAUL (GB) | 2003-01-02 | — | — | US | disclosed |
| EP-1072601-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | HRH2, HRH4, HRH1 | OPRD1 4/4885OPRM1 9/4885OPRL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.